Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.49 |
| ▸ | GUCY1B2 | O75343 | 2/20 | 0.42 |
| ▸ | GUCY1A2 | P33402 | 2/20 | 0.42 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.42 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019688 | 0.92 | ADORA2A (0.49) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL4562728 | 0.88 | ADORA2A (0.45) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL5019689 | 0.87 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL4562319 | 0.87 | ADORA2A (0.50) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL5019563 | 0.86 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL5019580 | 0.85 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL5019595 | 0.84 | ADORA2A (0.50) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL4560977 | 0.83 | ADORA2A (0.51) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL5019575 | 0.82 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 | |
| SCHEMBL5019647 | 0.82 | ADORA2A (0.46) | ADORA2AADORA1ADORA3ADORA2BGUCY1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112845-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112845-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112845-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| EP-2637659-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2637659-B1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20150250795-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150250795-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-20150250795-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-9061030-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061030-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061030-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140088071-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088071-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088071-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2637659-A1 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064559-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064559-A1 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250795-A1 | sGC STIMULATORS | PTGIS, GUCY1B1, GUCY1A1 | ADORA2A 1750/4885ADORA1 1980/4885ADORA3 2854/4885 |
| US-20140088071-A1 | sGC STIMULATORS | PTGIS, GUCY1B1, GUCY1A1 | ADORA2A 1536/4885ADORA1 1758/4885ADORA3 2643/4885 |
| US-20170112845-A1 | sGC STIMULATORS | PTGIS, GUCY1B1, GUCY1A1 | ADORA2A 1750/4885ADORA1 1980/4885ADORA3 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.